State Street Corp Acquires 18,125 Shares of Cortexyme, Inc. (NASDAQ:CRTX)

Share on StockTwits

State Street Corp raised its holdings in Cortexyme, Inc. (NASDAQ:CRTX) by 10.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 194,052 shares of the biopharmaceutical company’s stock after acquiring an additional 18,125 shares during the period. State Street Corp owned about 0.66% of Cortexyme worth $8,851,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. Parallel Advisors LLC bought a new stake in shares of Cortexyme during the first quarter worth about $43,000. Golden State Wealth Management LLC bought a new stake in shares of Cortexyme during the first quarter worth about $46,000. Victory Capital Management Inc. grew its holdings in shares of Cortexyme by 109.2% during the fourth quarter. Victory Capital Management Inc. now owns 1,665 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 869 shares during the last quarter. Botty Investors LLC grew its holdings in shares of Cortexyme by 100.0% during the first quarter. Botty Investors LLC now owns 3,062 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 1,531 shares during the last quarter. Finally, Citigroup Inc. grew its holdings in shares of Cortexyme by 50.0% during the first quarter. Citigroup Inc. now owns 3,470 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 1,157 shares during the last quarter. Hedge funds and other institutional investors own 38.29% of the company’s stock.

Shares of CRTX opened at $39.85 on Friday. Cortexyme, Inc. has a 52-week low of $19.35 and a 52-week high of $73.84. The business’s 50 day moving average price is $46.21 and its two-hundred day moving average price is $47.48. The firm has a market cap of $1.17 billion, a PE ratio of -19.83 and a beta of 1.79.

Cortexyme (NASDAQ:CRTX) last issued its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.16). As a group, equities research analysts expect that Cortexyme, Inc. will post -2.57 EPS for the current fiscal year.

In other news, insider Epiq Capital Group, Llc bought 6,085 shares of the stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $57.95 per share, with a total value of $352,625.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Lamond bought 5,448 shares of the stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $48.93 per share, for a total transaction of $266,570.64. Following the completion of the transaction, the director now directly owns 301,829 shares of the company’s stock, valued at $14,768,492.97. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 120,596 shares of company stock worth $5,944,646. Insiders own 19.80% of the company’s stock.

Several analysts have recently weighed in on the company. HC Wainwright assumed coverage on Cortexyme in a report on Wednesday, June 24th. They set a “buy” rating and a $76.00 price target on the stock. Jefferies Financial Group started coverage on Cortexyme in a report on Tuesday, June 2nd. They set a “buy” rating and a $59.00 price target on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $70.00 price objective (up from $42.00) on shares of Cortexyme in a research note on Wednesday, May 13th. ValuEngine lowered Cortexyme from a “buy” rating to a “hold” rating in a research note on Friday, June 5th. Finally, BidaskClub lowered Cortexyme from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Cortexyme currently has an average rating of “Hold” and a consensus target price of $62.50.

Cortexyme Company Profile

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.

Featured Story: How is an ETF different from a mutual fund?

Institutional Ownership by Quarter for Cortexyme (NASDAQ:CRTX)

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mackay Shields LLC Grows Stock Position in First Merchants Co.
Mackay Shields LLC Grows Stock Position in First Merchants Co.
Sealed Air Corp  Stock Holdings Lifted by Signaturefd LLC
Sealed Air Corp Stock Holdings Lifted by Signaturefd LLC
Signaturefd LLC Has $33,000 Stock Position in Vistra Energy Corp
Signaturefd LLC Has $33,000 Stock Position in Vistra Energy Corp
M&T Bank Corp Sells 702 Shares of Zions Bancorporation NA
M&T Bank Corp Sells 702 Shares of Zions Bancorporation NA
UBS Group AG Has $8.35 Million Position in Zions Bancorporation NA
UBS Group AG Has $8.35 Million Position in Zions Bancorporation NA
Signaturefd LLC Buys Shares of 1,000 InMode Ltd.
Signaturefd LLC Buys Shares of 1,000 InMode Ltd.


© 2006-2020 Ticker Report